NRD
RNAM

Nebula Research & Development’s Avidity Biosciences RNAM Stock Holding History

Nebula Research & Development’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-37,587
Closed -$340K – 956
2023
Q4 		$340K Buy
+37,587
New +$251K 0.1% 395

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Nebula Research & Development's RNAM Position: Q1 2024 in Review

Nebula Research & Development sold out of Avidity Biosciences (RNAM) in Q1 2024, closing a stake of 37,587 shares — an estimated $340K sold.

Nebula Research & Development first reported a position in RNAM in Q4 2023 and held it in 1 quarter. The position peaked at $340K in Q4 2023. 158 funds tracked by Wall St. Rank hold RNAM as of Q1 2024.

  • Nebula Research & Development reported no remaining Avidity Biosciences position as of Q1 2024 after selling out during the quarter.
  • Nebula Research & Development sold 37,587 Avidity Biosciences shares in Q1 2024, an estimated $340K.
  • Nebula Research & Development first reported a position in Avidity Biosciences in Q4 2023 and held it in 1 quarter.
  • Nebula Research & Development's Avidity Biosciences position peaked at $340K in Q4 2023.
  • 158 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2024.

Based on Nebula Research & Development's 13F filing for Q1 2024, filed 15 May 2024.